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Role of liver biopsy in nonalcoholic fatty liver disease
ILKe Nalbantoglu, Elizabeth M Brunt
ity, and location of fibrosis, as well as remodeling of the
parenchyma in NASH. This review focuses on the specific histologic lesions of NAFLD and NASH, grading and
staging, differential diagnoses to be considered, and
the continuing role of the liver biopsy in this important
liver disease.
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Core tip: Nonalcoholic fatty liver disease (NAFLD) is the
most common form of chronic liver disease; no clinical or serologic tests have yet replaced liver biopsy for
definitive diagnosis. The histologic spectrum includes
steatosis, steatohepatitis, and cirrhosis with or without
active steatohepatitis. Hepatocellular carcinoma may
occur in cirrhosis, or prior to cirrhosis. Liver biopsy provides vital data for patient care, clinical trials, and for
ongoing research into nuances of the disease process.
The histologic spectrum of NAFLD, features with coexistent diseases, differential diagnoses, grading and
staging methods and the role of liver biopsy, as well as
a brief description of non-invasive alternatives, are discussed.

Abstract
Nonalcoholic fatty liver disease (NAFLD), defined as
abnormal accumulation (> 5%) of hepatic triglyceride
without excess alcohol intake, is the most common
form of chronic liver disease in adults and children in
the United States. NAFLD encompasses a spectrum of
histologic findings including uncomplicated steatosis,
steatosis with inflammation and steatohepatitis [nonalcoholic steatohepatitis (NASH)]; the latter can advance
to cirrhosis and hepatocellular carcinoma. NASH is
currently accepted as the hepatic manifestation of the
set of cardiovascular risk factors collectively known as
metabolic syndrome. In 1999 a system for histologic
grading and staging for NASH was proposed; this was
revised by the NASH Clinical Research Network in 2005
for the entire spectrum of lesions in NAFLD, including
the lesions and patterns of pediatric NAFLD, and for
application in clinical research trials. Diagnosis remains
distinct from grade and stage. A recent European
proposal separates steatosis from activity to derive a
numeric diagnosis of NASH. Even though there have
been promising advancements in non-invasive testing,
these tests are not yet detailed enough to replace the
full range of findings provided by liver biopsy evaluation. Limitations of biopsy are acknowledged, but liver
biopsy remains the “gold standard” for diagnosis and
determination of amounts of necroinflammatory activ-
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD), defined as
abnormal accumulation of triglycerides in the liver (i.e., >
5%) in the absence of significant alcohol intake, is recog-
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nized as the most common cause of chronic liver disease,
and is estimated to affect 30% of adults and 10% of
children in United States[1]. The prevalence of NAFLD
parallels that of metabolic syndrome, insulin resistance,
type 2 diabetes and central obesity[2]. It is currently recognized that mortality in the majority of individuals with
NAFLD is more likely from cardiovascular diseases than
from liver disease[3], thus, even though recent studies
have documented similar epidemiologic and histologic
features of NAFLD and nonalcoholic steatohepatitis
(NASH) in the geriatric population[4,5], this age group will
not be further discussed in this review. The prevalence
is highest in the ethnic Hispanic population, followed by
non-Hispanic whites, Asians and African Americans[6,7].
The prevalence increases significantly up to 80%-90% in
obese adults, 60% in patients with hyperlipidemia, and
30%-50% in diabetics[2]. Only a minority of subjects with
steatohepatitis actually progress to fibrosis or cirrhosis[8].
Currently, however, NAFLD is the third most common
cause of liver transplantation in United States[9], and is
projected to be the leading cause of liver transplantation
in the United States by 2020[1]. In addition, approximately
4%-22% of hepatocellular carcinomas in the Western
world are attributed to NAFLD[10]. Hepatocellular carcinoma may develop in either cirrhosis or non-cirrhotic
NAFLD, as recently reviewed[10,11].
NAFLD is a spectrum of histologic lesions of steatosis at one end, and steatohepatitis and cirrhosis at the
other[12]. However, whether in a given patient there is actual “progression” from steatosis to steatohepatitis without concurrent clinical complications such as weight gain,
or new onset diabetes, has not been adequately studied.
What is accepted is that steatosis itself is considered
“non-progressive” whereas steatohepatitis is the constellation of lesions with potential to progress; this was first
shown in a seminal series of Matteoni et al[13]. Thus, the
ability of the liver biopsy is to separate individuals with
steatohepatitis from those with “only” steatosis (which
includes steatosis with inflammation); this is an important goal that any diagnostic test should meet. NASH is
defined histopathologically by the presence of a constellation of features: steatosis, lobular and portal inflammation and liver cell injury in the form of hepatocyte
ballooning. Initially, in adults, the ballooning and fibrosis
are in a zone 3 distribution; once abnormal matrix is
deposited (i.e., fibrosis), and architectural remodeling occurs, the zonality of injury is less apparent.
Many advances have occurred since the initial recognition that fatty liver disease could occur in overweight
and/or diabetic subjects who weren’t over-exposed
to alcohol by several researchers including Thaler[14],
Klatskin et al[15], Schaffner et al[16] and Ludwig et al[17] in the
late 1970’s and early 1980’s. These include histopathologic
work in humans with careful clinical correlations discerning the prevalence of NAFLD and NASH[18], the roles
of progenitor cells and the ductular reaction in fibrogenesis[18-21], and the role of innate and adaptive immunemediated mechanisms in steatohepatitis[22], progression
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of steatohepatitis to cirrhosis and hepatocellular carcinoma[10,23,24] and genetic and genomic underpinnings of
disease susceptibility and progression[25,26].

LIVER BIOPSY: ROLE, INDICATIONS,
AND DRAWBACKS
The general indications for performing a liver biopsy in
patients with NAFLD are to confirm or exclude the diagnosis, diagnose other liver diseases, and to determine
amounts of damage to the liver for treatment and prognosis. The last includes necroinflammatory activity, which
is potentially reversible, and collagen deposition with
varying degrees of remodeling, which is potentially less
reversible. More specific indications have been recently
stated. According to the 2012 guidelines from American
Association for the Study of Liver Disease (AASLD),
liver biopsy should be reserved for subjects who will
“benefit”, for subjects with potentially competing diagnoses, and for children with either an unclear diagnosis or in
whom consideration is being given for medication[27]. The
European Association for the Study of Liver Disease position statement on liver biopsy differed slightly and recommended liver biopsy in all bariatric surgery subjects,
and as an endpoint in all clinical trials[28]. Liver biopsy
remains the standard against which noninvasive (serologic
and imaging) methods are judged in order to assess these
features. By histologic evaluation, one is able to distinguish between NASH, a lesion with progressive potential,
and no NASH, lesions without potential to progress[28-33].
Performing a liver biopsy on every patient with suspected NAFLD remains a controversial subject in daily
practice, and clearly is not a practical consideration as a
“screening” tool. There are studies, however, that support
the value of liver biopsy. A frequently cited albeit older
study by Skelly et al[34] showed that of 354 biopsied patients
with otherwise unexplained abnormal liver tests 66% had
fatty liver, 50% of those had steatohepatitis, approximately
19% of the remaining biopsies had other treatable causes
diagnosed by the pathology evaluation including autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), hemochromatosis and alcoholic liver disease (ALD).
A more recent study used a modeling system to show
that obtaining a liver biopsy could provide survival benefit to patients with NAFLD. Gaidos et al[35] evaluated
the long-term benefit of biopsy vs no biopsy. The study
showed that performing an early liver biopsy resulted in a
higher percentage of having mild liver disease ultimately
in NAFLD patients. Early diagnosis and treatment resulted in decrease in progression to severe disease or
transplant and a predicted survival advantage in NAFLD
patients. In addition, the risk of death related to liver biopsy did not offset the survival advantage. Others have
demonstrated the benefits of liver biopsy in NAFLD
by demonstrating the presence of NAFLD or NASH in
“atypical settings” such as concurrent disease processes
such as Hepatitis C[36-38], AIH, PBC, hereditary hemochromatosis (HH)[36], as well as drugs and occupational
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exposures[39-41]. Liver biopsy studies proved the validity
of the concept of the presence of all ranges of necroinflammatory activity and fibrosis, including cirrhosis, in
the presence of normal alanine aminotransferase values
in adults[42-44], and children[45]. The current state of investigation for pathologists is to evaluate which subjects will
develop fibrosis and why, and which findings on early
biopsies, if any, may be predictive of future outcomes.
Liver biopsy studies have given insight into natural
history of NASH, albeit in a selected group of primarily adult subjects. The prevalence of NASH, 12.2% of
over 300 multi-ethnic adult subjects, was established in
a Texas city by liver biopsy in an unbiased community
who were willing to undergo ultrasound and subsequent
liver biopsy. Nearly 30% had evidence of NAFLD by
ultrasound[18]. This was the first study of its kind in
adults, as all prior studies had been done either in living
donors, who did not have evidence of steatohepatitis, or
in autopsies. Liver pathology evaluation was the first to
establish the remarkable incidence of fatty liver of up to
13% in an autopsy study of children who died from accidental deaths[46]. Liver biopsy further characterized the
association of cardiovascular disease and biopsy proven
NAFLD in 150 overweight children compared with 150
overweight children without NAFLD[47].
At the current time, it remains common practice to
attribute cases of cryptogenic cirrhosis to burned out
“NASH”. This is not altogether appropriate unless there
is prior biopsy proof of NASH because clinically it is
known that other forms of liver injury can “burn out”, in
particular alcoholic liver disease and autoimmune liver disease. It was liver biopsy studies that indicated that NASH
may be one of the underlying causes of cryptogenic cirrhosis, which, by definition, has no serologic markers for
determination of cause of liver disease. This was shown
in a small case series[48] then larger case studies comparing NAFLD-related cirrhosis to cirrhosis related to other
forms of serologically diagnosed chronic liver disease[49],
and finally in kindred studies[50]. Liver biopsy in cirrhosis
of otherwise unknown etiology can show evidence of
ongoing steatohepatitis, or burned out disease without
any activity or steatosis in subjects with clinical features
of metabolic syndrome. Additionally, not only will NASH
progress to advanced fibrosis and cirrhosis in a subset of
individuals if the underlying metabolic conditions are unchanged, but several studies have verified that NASH may
also regress spontaneously, as reviewed[51]. This phenomenon has largely been observed in either placebo arms or
in the non-responders of treatment trials[52-54].
In 2009, an AASLD sponsored workshop raised important questions for advancement in the field of NAFLD,
providing guidance for investigators for clinical design
and end points including pathologic and laboratory
data[55]. As evidenced by published recommendations, liver biopsy is an important tool in clinical trials. Outcomes
remain based on histologic features which provide information regarding the effects of intervention on extent
and severity of hepatocellular injury, inflammation, and
architectural alterations as well as the ultimate diagnosis.
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To date, histologic evaluation remains the “hard endpoint” that can be measured with the most reliability[12].
The most commonly used tool for histologic evaluation
is the nonalcoholic fatty liver disease activity score (NAS)
(Details will be discussed in later in the text). The NAS
was not intended to replace the diagnosis but to provide
a sensitive tool to assess the changes that might occur
with treatment[56]. However, unintended use of this score
has been noted by the investigators[56]. A study by NASH
clinical research network (CRN), including 976 adult liver
biopsies, challenged this concept and demonstrated that
while the NAS correlated with the diagnosis, it was in
the lower and higher ends of the spectrum. Therefore, if
NAS were to reflect the diagnosis, a significant portion
of these patients would be misclassified[56]. Most importantly diagnosis of NASH was strongly associated with
the presence of diabetes, quantitative insulin sensitivity
check index (QUICKi) and homeostasis model assessment-estimated insulin resistance (HOMA-IR)[56] while
the diagnosis and the NAS both correlated with aminotransferases. This data further supported the concept that
scoring lesions and diagnosing patterns of injury are different processes for a pathologist[29,56].

LIVER BIOPSY LIMITATIONS
Liver biopsy, as useful as it is, however, does have limitations. The major limitation of liver biopsy is the invasive
nature of the procedure. Though considered “minimal”,
liver biopsy is an invasive procedure and can have complications even in the ideal clinical conditions, including
pain, minor and major bleeding (0.3%). Organ perforation is uncommon, but more likely in blind biopsy. Death
albeit rare, has been reported at 0.01%[57]. Currently, the
majority of liver biopsies are performed under ultrasound
guidance. As with liver biopsy interpretation, operator
experience is an important factor in success[58].
As in other chronic liver diseases, biopsy size is an
important, but often unrecognized consideration in diagnostic accuracy[12,59,60]. A biopsy, at least 1.6 cm in length
with 1.2-1.8 mm diameter, containing approximately 10
portal tracts is considered adequate[61,62]. Even then an adequate liver biopsy represents approximately 1:50.000 of
the entire organ[63].
Some limitations of liver biopsy are due to variability
of the disease process itself, as with all other forms of
chronic liver disease. NAFLD, while a diffuse process of
the liver, can have differences particularly in fibrosis due
to the location of the samples under evaluation. The subcapsular liver tissue is generally more fibrotic, and the left
lobe has larger portal areas near the capsule than the right.
Thus, it is important, particularly for studies, that both pre
and post study biopsies are done in a similar fashion and
from the same region of the liver[12]. Authors have not
always agreed on the amounts of histologic sampling variability in NAFLD. Larson et al[62] found minimal variability
in steatosis, NAS ≥ 5 and fibrosis between two samples
in bariatric subjects. The study also emphasized the need
for not only appropriate length, but also width of liver bi-
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opsy needle. Another study in morbidly obese individuals
undergoing bariatric surgery found moderate histologic
variability between lobes[64]. In two additional studies, one
in bariatrics and one in non-morbidly obese subjects, two
separate biopsies from the same location in the same lobe
were graded and staged independently and showed one or
more points in discordance in fibrosis stage[59,60]. In addition hepatocyte ballooning, one of the diagnostic requirements of NASH, was not present in 24% of patients in
one study in one set of the biopsies[60]. The implications
for clinical studies for evaluating pre and post treatment
biopsies are apparent.
The experience of the pathologist also plays a significant role in making the diagnosis of NAFLD; this is
similar to other liver diseases[58]. The interobserver agreements on steatosis, ballooning and fibrosis were good
amongst pathologists in the study of Kleiner et al[65] that
included 32 adult biopsies and 9 pathologists but not so
strong for location of steatosis and for inflammation[66].
Similar observations were reported in a study of 21 liver
biopsies read by eight experienced Japanese hepatopathologists with good agreement on fibrosis and extent
of steatosis. Younossi et al[67], showed good concordance
for extent of steatosis and degree of fibrosis along with
ballooned hepatocytes in 53 liver biopsies interpreted by
4 experienced liver pathologists.
The high prevalence of NAFLD in the population and the limitations, risks and cost of liver biopsy
have led investigators to seek for non-invasive methods
to diagnose, and stage NALFD. The ideal test would
be cheap, reproducible, and would be able to diagnose
the full spectrum of NAFLD, predict fibrosis, and also
reflect changes that occur with treatment[31,32]. Several
different methodologies including imaging modalities,
serum markers and combined tests are currently being
investigated. Even though advancements are being made
in these fields, none of these can provide detailed and accurate enough information to replace the liver biopsy. For
a more comprehensive summary of recent non-invasive
tests, the reader is referred to current reviews[31,32].
In summary an adequate liver biopsy, with appropriate
clinical history, interpreted by a trained liver pathologist,
is not only pivotal for an accurate and complete diagnosis
(or exclusion) of NAFLD (or NASH), but also is optimal
for obtaining detailed information regarding disease pattern, severity and fibrosis. It provides important information with respect to subtypes, potential future risks,
possible etiology, and natural history of disease, and sets
the ground work for future molecular studies and clinical
trials, assisting clinical colleagues and patients with treatments and follow-up.

entertained. Steatosis initially is found predominantly in
hepatocytes around the terminal hepatic venule (zone
3); when abundant, steatosis can be panacinar, and when
resolving, may be irregular, or azonal. The type of triglyceride accumulation that is observed in NAFLD is
predominantly macrovesicular and is typically characterized by a single or a few lipid droplets within the affected
hepatocytes, displacing the nucleus peripherally within
the cell (Figure 1A). When the droplets are smaller, i.e.,
“small droplet” steatosis, they are well-defined and easily
delineated from one another. Small droplets often form
droplets around the larger droplets and may coalesce
to form the macrodroplet. Albeit small, these types of
droplets should not be confused for true “microvesicular”
steatosis, as the pathophysiology and thus implications
for liver function differ (Figure 1B). Microvesicular steatosis may occur in a patchy distribution in up to 10 % of
NASH cases[68,69], and has been shown in a large study to
be associated with ballooned hepatocytes, and advanced
fibrosis[69].
There are a constellation of histopathologic lesions
required for the diagnosis of steatohepatitis. These include steatosis, inflammation (lobular and portal) and
hepatocyte injury, commonly in the form of ballooning.
Ballooned hepatocytes appear as enlarged hepatocytes
with a flocculent, cleared appearance of the cytoplasm
with irregular cytoplasmic borders[30,70] (Figure 1C). Often
the nucleus is hyperchromatic. Hepatocyte ballooning has
been shown to correlate with oxidative damage[71] and microtubule disruption[30,70], and loss of normal structure of
the cytoskeleton[71,72]. In adult NASH, ballooned hepatocytes are most commonly seen in zone 3 and if fibrosis is
present, they are intermixed with perisinusoidal collagen
fibers. Keratins 8/18, present throughout the cytoplasm
of all normal hepatocytes[72], are damaged in ballooned
hepatocytes; this is manifest with loss of cytoplasmic
immunoexpression (Figure 1D), movement to submembranous location, and highlighting of Mallory-Denk
bodies (MDB)[73]. MDB are ubiquitinated keratins and cytoskeletal structures within the proteosome (Figure 1E).
p62 and ubiquitin are immunomarkers that label MDB[74].
By trichrome stain, MDB can be blue or green (Figure
1F). In NASH, MDBs are often less well-formed than in
alcoholic hepatitis or alcoholic steatohepatitis[75]. Finally,
ballooning has been associated with several relevant clinical markers such as measures of insulin resistance[76],
increased serum cholesterol[76,77] and serum markers of
necroinflammation[78]. Similar correlations have also been
noted in the pediatric population[79].
Lobular inflammation, typically more prominent than
portal inflammation in uncomplicated adult NAFLD,
is mostly mononuclear, but also includes Kupffer cell
clusters, microgranulomas with or without lipid droplets,
and larger lipogranulomas (Figure 1G). Lefkowitch noted
prominent enlargement and aggregation of Kupffer cells
around terminal hepatic venules in NASH, in contrast to
the even distribution in normal livers and uncomplicated
steatosis[80]. Kupffer cells, the largest resident macrophage

HISTOLOGIC FEATURES, GRADING, AND
STAGING OF NAFLD: ADULTS
In NAFLD, 5% or more macrovesicular steatosis is required for the diagnosis. This may occur with or without
other findings, but without it, the diagnosis cannot be
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Figure 1 Histologic features, grading, and staging of nonalcoholic fatty liver disease. A: Mixed large and small droplet steatosis, single droplet, with nucleus
pushed to one side, HE stain, 600 ×; B: Microvesicular steatosis, nuclei in the center with foamy cytoplasm, and megamitochondria HE stain, 600 ×; C: Ballooned
hepatocytes with flocculent cytoplasm, HE stain, 600 ×; D: Loss of cytoplasmic expression of keratin 8/18 in ballooned hepatocytes, 600 ×; E: Mallory-Denk body, HE
stain, 600 ×; F: Mallory-Denk body in blue-green color and dense perisinusoidal fibrosis, Trichrome stain, 600 ×; G: Portal lipogranuloma, HE stain, 400 ×; H: MalloryDenk bodies and satellitosis HE stain, 600 ×; I: Delicate perisinusoidal fibrosis, Trichrome stain, 600 ×; J: Bridging fibrosis, Trichrome stain, 200 ×.

population in liver, are an important component of the
innate immune system[81] and are implicated in the development and the progression of steatohepatitis[82,83] as well
as in fibrosis[83].
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Occasional polymorphonuclear leukocytes may also
occur as a part of lobular inflammation. When intense
and encircling hepatocytes (i.e., satellitosis), one should
consider alcoholic hepatitis (Figure 1H). The intensity
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and distribution of the inflammation varies within the
lobule. In some cases, the intense inflammation in zone
3 may be confused with a portal area with the duct obscured by inflammation. This may be particularly true in
the cases when an artery branch is readily appreciated in
zone 3[84].
Portal inflammation in NAFLD/NASH can be seen
in 4 situations in increased amounts. In most cases, however, it is usually milder than lobular inflammation, and
mononuclear cells are typically predominant[85]. Increased
portal inflammation in active NASH has been associated with increased steatosis, ballooning and fibrosis in
a series of 728 adult and 205 pediatric biopsies[86]. Additionally, portal inflammation was noted to predominate
along with portal fibrosis in a study of 100 pediatric
NAFLD biopsies[87]. When portal inflammation is unusually prevalent, or when lymphoid aggregates occur in
adult NAFLD or NASH, one should consider the possibility of a concurrent liver disease such as viral hepatitis,
autoimmune liver disease, as examples[36,88]. Liver biopsy
data has shown that pathologists are capable of diagnosing NASH concurrently with another serologically
positive liver disease, in particular, HCV, but the criteria
may differ. This concept was shown by 3 separate studies; 2 retrospective reviews of large biopsy series[36,38]
and a prospective study[89]. One group emphasized the
necessity of stricter histologic criteria when evaluating
NASH with other diseases by focusing on the characteristic zone 3 perisinusoidal fibrosis of the former that
does not occur in the latter[36]. The fourth consideration
is increased portal inflammation compared to lobular
in adult patients following otherwise effective intervention[29]. Finally, a different type of portal inflammation,
i.e., polymorphonuclear leukocytes accompanying periportal ductular reaction may be indicative of ALD with
pancreatitis or other forms of biliary obstruction.
Studies have demonstrated expansion of the periportal progenitor cell compartment in NASH. Hepatic
progenitor cells (HPC) reside within the canal of Hering, along the limiting plate. They are rarely visualized by
light microscopy unless activated. HPC are characterized
by high N:C, round to spindled cytoplasm, ovoid nuclei
and positivity for keratin 7 and 19; these characteristics
are altered with progressive stages of development towards hepatocellular or biliary epithelium. In certain circumstances of liver injury and repair, stem cell markers,
Hedgehog pathway markers and others are also reported
in activated HPC[90]. Roskams et al[91] demonstrated increased number of progenitor cells in patients with
NASH and ALD; the study further showed correlation
between numbers of hepatic progenitor cells and fibrosis
stage. In a multi-center study of subjects before and after
various forms of treatment, the investigators demonstrated expansion of progenitor cell component, correlation
between ductular reaction, steatosis, amount of portal inflammation, and NASH activity grade[19]. The group went
on to demonstrate that the ductular reaction correlated
with p21 positive replicative arrest in hepatocytes which
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was also associated with NASH activity and with insulin
resistance. This area of epithelial-mesenchymal communication is one of ongoing interest in NASH.
Apoptotic hepatocytes are common both in NASH
and ALD. Investigators have found that increased apoptosis is associated with disease severity[92,93], as well as
fibrosis in NASH[92].
Isolated arteries observed in zone 3 correlated with
advanced fibrosis in NASH[84]. Care must be taken to
not confuse this region for a portal tract when there is
marked inflammation.
Iron deposition, typically mild, can be noted as punctate granules within reticuloendothelial lining cells and
as granules or blush within hepatocytes. It has been reported in 15%-55% of cases[94]. Reticuloendothelial iron
deposition was associated with steatosis, ballooning, portal inflammation, and fibrosis in a study of 849 patient
biopsies from the NASH CRN[95,96]. The relationships of
iron deposition, hepcidin, iron regulatory genetics, advanced fibrosis and insulin resistance in fatty liver disease
are complex and under intense investigation[96-99].
The typical pattern of fibrosis in adult NASH is initially located in zone 3 in the perisinusoidal spaces in a
pattern that is described as pericellular. When delicate, it
is best appreciated with Masson trichrome or other collagen stains (Figure 1I). As the disease progresses, the
fibrosis becomes denser in zone 3 perisinusoidal spaces
and, with further progression, portal and periportal fibrosis can be appreciated. At that point, ductular reaction is
often present. In time, central-central, central-portal, or
portal-portal bridging, architectural remodeling and finally cirrhosis may occur (Figure 1J). In the advanced stages
of fibrosis and remodeled architecture, perisinusoidal
fibrosis may no longer be present. Cartoon depiction of
progression may be seen in texts[100].

GRADING AND STAGING THE LESIONS
OF NAFLD/NASH
In 1999, a semi-quantitative grading and staging system
to describe and unify the approach of pathologists to the
histopathologic lesions of NASH and fibrosis along with
architectural alterations, was proposed by Brunt et al[101].
The system was developed from evaluation of 51 liver
biopsies of NASH, and followed the broad method
recently developed for chronic hepatitis of separating
activity (grade) from fibrosis (stage), with the recognition
that NASH was not a portal-based process[102]. A semiquantitative activity grade was assigned by a combination
of parameters including steatosis, lobular and portal inflammation, and hepatocyte ballooning (Table 1). Fibrosis staging was based on fibrosis patterns of adult NASH,
and reflects the progression of fibrosis as well as subsequent architectural remodeling. Figures 1I and J illustrate
Stages 1 and 3. The details of staging system can be seen
in Table 2.
In 2002 the Brunt grading and staging was revised by
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Table 1 Brunt grading system
Grade
Mild (1)
Moderate (2)
Severe (3)

Table 3 Nonalcoholic steatohepatitis clinical research network nonalcoholic fatty liver disease scoring system

Steatosis

Ballooning

Inflammation

1-2 (< 66%)
2-3
2-3

Minimal
Present-zone 3
Marked-zone 3

L: 1-2 P: 0-1
L: 2 P: 1-2
L: 3 P: 1-2

Steatosis grade
0: < 5%
1: 5%-33%
2: 34%-66%

Reproduced with permission[101]. Steatosis: grade 1: < 33%; grade 2: >
33%-66%; grade 3: > 66%. Lobular inflammation: grade 1: < 2 foci per 200
× field; grade 2: 2-4 foci per 200 × field; grade 3: > 4 foci per 200 × field.
Portal inflammation: grade 0: None; grade 1: Mild; grade 2: Moderate;
grade 3: Severe. Ballooning: grade 1: Rare; grade 2: Prominent ballooning.
L: Lobular/acinar inflammation; P: Portal inflammation.

3: > 66%

Lobular inflammation

Liver cell ballooning

0: No foci
0: None
1: < 2 foci per 200 × field 1: Few ballooned hepatocytes
2: 2-4 foci per 200 × field
2: Many ballooned
hepatocytes
3: > 4 foci per 200 × field

Reproduced with permission[65]. Nonalcoholic fatty liver disease activity
score (NAS): Steatosis + inflammation + ballooning. Fibrosis, 0: None; 1:
Perisinusoidal or periportal; 1A: Mild, zone 3 perisinusoidal; 1B: Moderate, zone 3 perisinusoidal; 1C: Portal, periportal; 2: Perisinusoidal and
portal/periportal; 3: Bridging fibrosis; 4: Cirrhosis.

Table 2 Brunt staging system
Stage
1
2
3
4

Zone 3 PSF, focal or Portal, periportal Bridging
extensive
+
+
+/+/-

0
+
+/+/-

0
0
+
+/-

sessments of portal inflammation into account. Further
validation of this method in non-morbidly obese subjects
is awaited.
In summary, grading and staging systems are useful tools in terms of providing a standard in pathology
reporting, monitoring response to treatment and/or
progression of disease both in patient care and clinical
trials. However, the diagnosis of NAFLD depends on
interpreting a variety of histologic findings and patterns
and, cannot be replaced or reflected with a single number
or score.

Cirrhosis
0
0
0
+

Reproduced with permission[101]. PSF: Perisinusoidal fibrosis.

NASH CRN for use as a feature-based system in clinical
trials. The system was published in 2005, and has come
to be known as “NAFLD Activity Score (NAS)”[65]. The
NASH CRN Scoring system includes the entire spectrum
of lesions that can be seen in the full range of NAFLD
and NASH, including pediatric liver disease (Table 3).
The disease activity score represents the unweighted sum
of scores for steatosis, hepatocyte ballooning, and lobular
inflammation. The fibrosis stage is an expansion of the
Brunt scoring, with additional subdivisions to stage 1 (1amild perisinusoidal fibrosis, 1b-moderate perisinusoidal
fibrosis, and 1c-portal fibrosis only, as occurs in pediatric
NAFLD).
Alkhouri et al[103] recently published a calculated pediatric NAFLD histological score (PNHS), using the
histologic parameters in NAS. The PNHS consists of
weighted sum of steatosis, hepatocyte ballooning, lobular
inflammation and portal inflammation. The “borderline
NASH” category has been eliminated from the pediatric
scoring system and high scores are associated with a diagnosis of NASH in this patient group[103]. The reader is
referred to the reference for the calculation.
Most recently, an algorithmic approach to scoring
has been proposed by Bedossa et al[104] based on over
600 bariatric patient liver biopsies. The SAF (steatosis,
activity, fibrosis) system is a sum of scores of steatosis,
activity (hepatocyte ballooning + lobular inflammation)
and fibrosis. Many details are modeled on the criteria by
NASH CRN[65]. The SAF system differs from NAS in
three major areas: it includes fibrosis into the final score,
it excludes steatosis from the activity score and one is
able to derive a diagnosis of NASH from a numeric value
of SAF. It is noteworthy that the proponents of this system do not take patterns of any of the lesions or any as-
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PEDIATRIC NAFLD
One of the most consistent observations of pediatric
NAFLD that differed from adults was the difference in
distribution of the fat, and the preferential accentuation
of portal inflammation and fibrosis (Figure 2A, B). Steatosis is commonly either panacinar or distinctly periportal
(zone 1)[87,105-107]. From a study that resulted in a hierarchical analysis of 100 pediatric biopsies, Schwimmer proposed two dominant subtypes of pediatric NAFLD: Type
1, the least common, but seen in Caucasian girls and with
the similar zone 3 accentuation as with adult NAFLD, and
Type 2, the most common, seen more often in boys and
characterized by either panacinar or periportal steatosis,
portal-predominant inflammation and portal-based fibrosis, and most commonly encountered in Asian, Hispanic
or Native American ethnic groups. The remainder of the
biopsies were “overlap” or steatosis[87]. Carter-Kent et al[108]
studied a large multi-ethnic overweight biopsy population
from several North American centers and found less ability to clearly separate the biopsies into discrete patterns
with an overlap of the two main patterns in 82% of cases.
Nobili et al[109] also noted more overlap (52.4%) than either
Type 1 or 2 in a series of 84 Italian overweight subjects.
The NASH CRN refers to zone 1 (periportal) pattern as
“borderline, zone 1”, and zone 3 pattern as “borderline,
zone 3”, and has found similar ethnic correlations to Patton et al[110]. Both patterns have been seen in blinded biopsy reviews by the Central Pathology Committee in adult
biopsies, albeit in small numbers. Interestingly, to date,
there is yet to be a definitive agreement amongst expert
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A

B

Figure 2 Pediatric nonalcoholic fatty liver disease. A: Periportal accentuation of steatosis with sparing of zone 3, pediatric nonalcoholic fatty liver disease (NAFLD),
HE stain, 200 ×; B: Portal fibrosis without zone 3 perisinusoidal fibrosis, pediatric NAFLD, Trichrome stain, 100 ×.

pathologists in the field for pediatric NASH histology, unless there are the very same characteristics found in adult
NASH, as described above. There is also no knowledge
about when or how a transition may occur from pediatric patterns to adult patterns of disease, but an initial
retrospective cross-sectional review of 186 NASH CRN
biopsies has shown that comparing biopsies from children during prepuberty, puberty and post puberty, there
is less steatosis and portal inflammation, but increased
steatohepatitis and Mallory-Denk bodies with the change
in age[111]. These findings are strongly suggestive that with
the changes of aging and associated hormonal alterations
and shifts of insulin sensitivity, the liver is more susceptible to the injury of increased free fatty acids and lipotoxicity. Natural history studies with prospective biopsies are
needed in this growing population.
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